GlucoTrack unit Lokahi Therapeutics targets single-shot LT-100 dosing in planned Q4 2026 trial
PUBT · 23h ago
Share
Listen to the news
- Lōkahi Therapeutics, a wholly owned GlucoTrack unit, advanced plans to shift LT-100 dosing to a single subcutaneous injection per visit.
- Program aims to replace the historical regimen of up to 15 intradermal injections per treatment visit.
- Strategy follows a May 2026 FDA Type C meeting, supported by a minipig study comparing subcutaneous versus intradermal systemic exposure.
- Clinical evaluation of the single-injection approach targeted as early as Q4 2026, with an initial readout expected in H1 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260729962665) on July 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved